Advs. Micki Shapira, Daniel Green and Sophy Litvin represented Fosun Health Fund (the venture capital arm of Fosun Pharma) in an exclusive license and supply agreement with Raziel Therapeutics to develop and commercialize Raziel's proprietary RZL-012, an injection used for reducing double chins, in mainland China, Hong Kong, Macau, and Taiwan for milestone payments of up to $74 million plus tiered royalties on future sales. The team was joined by advs. Miriam Friedmann, Inbar Hakimian-Nahari and intern Yang Cheng.
Advs. Ben Sandler and Barry Levenfeld represented orthologics company Bioventus in its investment in the Israeli medical device company Cartiheal, including in signing an option to buy it. Assisted alongside David Roness, Ofir Levy, Daniel Marcovici, Daniel Green, Eli Greenbaum, Guy Fuhrer, Miriam Friedmann, Shira Teger, Tali Har-Oz, Hadar Stein, Chaim Cohen, Chaya Alexandra Y.N. Kong, Sophy Litvin, Nir Kamhi, Ofir Paz, Shmuel Brill and interns Noah Levy, Katya Kagantsov and Danya Sakols.
Adv. Tamar Tavory recently joined our firm as special counsel and will be strengthening the firm’s digital health practice, with a particular focus on telehealth, AI in medicine, medical research, and secondary use of medical data.
Advs. Barry Levenfeld, Adrian Daniels, Noah Zivan, Vered Glaubach and intern Nitzan Bigman represented Barclays in their role as underwriters in the IPO of clinical-stage bio-pharmaceutical company PolyPid on Nasdaq, in which $60 million were raised. They were joined by Shira Lahat, Daniel Green, Miriam Friedmann, Sophy Litvin, Dr. Eran Lempert, Assaf Mesica and Shai Margalit.
Advs. Simon Weintraub, Daniel Green, Shira Teger and Tali Har-Oz represented Prilenia Therapeutics in a Series A financing round in which it raised 62.5 million dollars. The new funds will be used for two late-stage trials, which could lead to the registration of pridopidine for the treatment of HD and ALS.
Advs. Barry Levenfeld, Ben Sandler, Evan Schendler, Alona Toledano, Ofir Levy, Shay Fahima, Yoheved Novogroder Shoshan, Daniel Green, Miriam Friedmann, Tali Har-Oz and the interns Itamar Ben David, Hadar Stein and Elad Cohen represented the med-tech giant Stryker in the acquisition of Orthospace Ltd, an Israeli company that has developed a device for treating serious shoulder pain, for $220 million.
Yigal Arnon & Co. in cooperation with IATI (Israel Advanced Technology Industries) invite Hi-Tech & Life Science Start-ups to join us in the event: “The Ins-and-Outs of the Due Diligence Process in Investment Transactions”, October 23, 2013, Yigal Arnon & Co. offices.
Advocates Barry Levenfeld, Harry Kirsh, Yuval Shalhevet, Zohar Nevo and Noam Enk represents the winning bidding consortium, consisting of Johnson & Johnson, Takeda Pharmaceuticals (the first Japanese Pharmaceutical Company to invest in Israel) and the healthcare fund OrbiMed Israel, for the establishment of an OCS-supported biotechnological incubator intended to encourage the creation and support of pharmaceutical and medical device companies.
Advs. Barry Levenfeld, Eric Spindel, Avigail Frisch and Noam Enk represented Aegis for Alcobra Ltd.'s initial public offering on Nasdaq. Alcobra Ltd., headquartered in Israel, is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug to treat Attention Deficit Hyperactivity Disorder.
Advocates Barry Levenfeld, Ben Sandler, Harry Kirsh, Avigail Frisch and Zohar Nevo represented Stryker, an U.S.-based leader in worldwide orthopedic medical technology in the acquisition of the Israeli company Surpass Medical, which develops and commercializes next-generation flow diversion technology to treat brain aneurysms, for $135 million.